SLC45A3: A Potential Drug Target and Cancer-Associated Gene (G85414)

Target Name: SLC45A3

NCBI ID: G85414

SLC45A3

SLC45A3: A Potential Drug Target and Cancer-Associated Gene

SLC45A3, also known as SLC45A3 gene orAbsC2 gene, is a member of the Absolutely conserved gene family 2 (ABC2) and the SLC45 family. It is a gene that encodes a protein known as ABC2, which is a type of carrier protein that plays a crucial role in intracellular signaling.

The ABC2 protein is composed of 254 amino acid residues and has a calculated molecular weight of 31.1 kDa. It has a unique structure that consists of a N-terminal transmembrane domain, a cytoplasmic domain, and an C-terminal TIR domain. The N-terminal transmembrane domain, a cytoplasmic domain, and an C-terminal TIR domain. terminal transmembrane domain is responsible for the protein's ability to interact with various intracellular signaling pathways, while the cytoplasmic domain and TIR domain are involved in protein stability and interactions with other cellular components.

SLC45A3 is expressed in most tissues and cells of the human body, including the brain, heart, liver, and pancreas. It is also a well-established cancer-associated gene that has been implicated in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer.

One of the most significant aspects of SLC45A3 is its potential as a drug target. The ABC2 protein has been shown to play a role in a variety of cellular processes, including cell signaling, migration, and invasion. Additionally, studies have suggested that ABC2 may be involved in the development of cancer.

SLC45A3 has also been shown to interact with several potential drug targets, including the transcription factorNrf2 and the protein heat shock protein (Hsp70)7. These interactions may render ABC2 a potential drug target for interventions aimed at modulating these pathways.

SLC45A3 has also been implicated in the regulation of cellular processes that are important for overall cellular health and longevity. For example, studies have shown that ABC2 plays a role in the regulation of cell cycle progression and the apoptosis process.

In addition to its potential as a drug target, SLC45A3 is also a potential biomarker for several types of cancer. The ABC2 protein has been shown to be overexpressed in several types of cancer, including breast, ovarian, and prostate cancer. This overexpression can be used as a biomarker for these cancers, as it may be an indicator of the disease.

Another potential application of SLC45A3 is its use as a target for small molecules. The ABC2 protein has been shown to have multiple interactions with small molecules, including inhibitors of the protein kinase (PKP) and the DNA-binding protein p53. These interactions may make ABC2 a potential target for the development of small molecules with anti-cancer or anti-inflammatory effects.

In conclusion, SLC45A3 is a well-established gene that has been implicated in a variety of cellular processes and has been shown to play a role in the development and progression of cancer. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the role of SLC45A3 in cellular processes and its potential as a therapeutic intervention.

Protein Name: Solute Carrier Family 45 Member 3

Functions: Proton-associated sucrose transporter. May be able to transport also glucose and fructose

The "SLC45A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC45A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets